Zai Lab has reported positive outcomes from its Phase III clinical trial of KarXT (xanomeline and trospium chloride) in China ...

Shares of Zai Lab rocketed to a 16-month high Thursday after the Chinese biotech posted "impressive" results for its lung cancer treatment.

Zai Lab (NASDAQ:ZLAB) reported positive topline data from a Phase 3 study in China for KarXT in the treatment of schizophrenia. The Chinese company said the study, a registrational bridging trial, met ...

After the recent FDA approval for the promising schizophrenia drug Cobenfy (xanomeline and trospium chloride), Bristol Myers ...

Zai Lab (ZLAB) announced positive topline results from the company’s Phase 3 multi-center trial evaluating the safety and efficacy of ...

Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest ...

Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price ...

Cantor Fitzgerald restated their overweight rating on shares of Zai Lab (NASDAQ:ZLAB – Free Report) in a research note issued to investors on Friday, Benzinga reports. Separately, JPMorgan Chase ...

Zai Lab (ZLAB) presented data from the ongoing global Phase 1a/1b study of ZL-1310, a next-generation antibody-drug conjugate, or ADC, at the ...

Zai Lab (NASDAQ:ZLAB) reported positive topline data from a Phase 3 study in China for KarXT in the treatment of schizophrenia. The FDA approved KarXT for schizophrenia in September. The drug will ...

Zai Lab has reported positive outcomes from its Phase III clinical trial of KarXT (xanomeline and trospium chloride) in China to treat schizophrenia. The registrational bridging trial, which ...